title: Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
abstract: We investigated whether the efficacy of fenretinide (HPR) against ovarian tumours may be limited by induction of resistance. The human ovarian carcinoma cell line A2780, which is sensitive to a pharmacologically achievable HPR concentration (IC(50)= 1 microM), became 10-fold more resistant after exposure to increasing HPR concentrations. The cells (A2780/HPR) did not show cross-resistance to the synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) and were not sensitive, similarly to the parent line, to all-trans-retinoic acid, 13-cis-retinoic acid or N-(4-methoxyphenyl)retinamide. A2780/HPR cells showed, compared to parental cells, a 3-fold reduction in colony-forming ability in agar. The development of HPR resistance was associated with a marked increase in retinoic acid receptor beta (RARbeta) mRNA and protein levels, which decreased, together with drug resistance, after drug removal. The expression of cell surface molecules associated with tumour progression including HER-2, laminin receptor and beta1 integrin was markedly reduced. The increase in the levels of reactive oxygen species is not involved in HPR-resistance because it was similar in parental and resistant cells. Conversely differences in pharmacokinetics may account for resistance because, in A2780/HPR cells, intracellular peak drug levels were 2 times lower than in A2780 cells and an as yet unidentified polar metabolite was present. These data suggest that acquired resistance to HPR is associated with changes in marker expression, suggestive of a more differentiated status and may be explained, at least in part, by reduced drug accumulation and increased metabolism.
authors.affiliation: Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, 20133, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Appierto
authors.forename: E
authors.initials: E
authors.lastname: Cavadini
authors.forename: R
authors.initials: R
authors.lastname: Pergolizzi
authors.forename: L
authors.initials: L
authors.lastname: Cleris
authors.forename: R
authors.initials: R
authors.lastname: Lotan
authors.forename: S
authors.initials: S
authors.lastname: Canevari
authors.forename: F
authors.initials: F
authors.lastname: Formelli
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000032:analysis; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology*; D002454:Cell Differentiation / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm; D005260:Female; D017313:Fenretinide / Q000493:pharmacokinetics* / Q000494:pharmacology; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology*; D018168:Receptors, Retinoic Acid / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018168:Receptors, Retinoic Acid; D017313:Fenretinide